Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.69
- Piotroski Score 4.00
- Grade Equal-Weight
- Symbol (APLS)
- Company Apellis Pharmaceuticals, Inc.
- Price $27.74
- Changes Percentage (0.91%)
- Change $0.25
- Day Low $26.62
- Day High $28.14
- Year High $73.80
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $76.00
- High Stock Price Target $113.00
- Low Stock Price Target $39.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.43
- Trailing P/E Ratio -11.77
- Forward P/E Ratio -11.77
- P/E Growth -11.77
- Net Income $-528,628,000
Income Statement
Quarterly
Annual
Latest News of APLS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Should You Hold Apellis Pharmaceuticals (APLS)?
PGIM Jennison Health Sciences Fund's Q2 2024 investor letter discusses its performance, highlighting Apellis Pharmaceuticals, Inc. (APLS) as a key stock. Despite a decline, the fund sees potential in ...
By Yahoo! Finance | 1 month ago -
Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds' Top Biotech Stock Picks
Insider Monkey analyzed the top biotech hedge funds and their stock picks, focusing on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Biotech stocks are risky due to clinical trials' impact on stock ret...
By Yahoo! Finance | 2 months ago -
Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Apellis Pharmaceuticals is a biopharmaceutical company focusing on rare diseases. Its drug SYFOVRE shows strong demand, with projected growth. With 38 hedge funds holding stakes, APLS ranks 10th in th...
By Yahoo! Finance | 2 months ago
